NEUROCRINE BIOSCIENCES INC (NBIX:NASDAQ)
$128.89 -2.75 (-2.089%)
Analysed NEUROCRINE BIOSCIENCES INC (NBIX:NASDAQ) News Sources
Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia
12-04-2026
yahoo.com
Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why
08-04-2026
yahoo.com
Assessing Neurocrine Biosciences (NBIX) Valuation As Long Term Returns Outpace A Richer Earnings Multiple
07-04-2026
yahoo.com
Neurocrine Soleno Deal Adds Vykat XR And Alters Valuation Story
07-04-2026
yahoo.com
Arm downgraded, Arista Networks upgraded: Wall Street's top analyst calls
07-04-2026
yahoo.com
Company News for Apr 7, 2026
07-04-2026
yahoo.com
Neurocrine to acquire Soleno in $2.9bn transaction
07-04-2026
pharmaceutical-technology.com
Soleno Therapeutics (SLNO) Soars 32% on $2.9-Billion Merger
07-04-2026
yahoo.com
Neurocrine Scoops Up Hunger-Drug Maker in Latest Multi-Billion-Dollar Pharma Deal
07-04-2026
thedailyupside.com
Stock Market Today, April 6: Soleno Therapeutics Climbs After $2.9 Billion All-Cash Buyout Agreement
06-04-2026
fool.com
What is the current price of NEUROCRINE BIOSCIENCES INC (NBIX:NASDAQ)?
The current price of NEUROCRINE BIOSCIENCES INC (NBIX:NASDAQ) is $128.89.
NEUROCRINE BIOSCIENCES INC (NBIX:NASDAQ) absolute price change since previous trading day?
The absolute price change of NEUROCRINE BIOSCIENCES INC (NBIX:NASDAQ) since the previous trading day is $-2.75.
NEUROCRINE BIOSCIENCES INC (NBIX:NASDAQ) percentage price change since previous trading day?
The percentage price change of NEUROCRINE BIOSCIENCES INC (NBIX:NASDAQ) since the previous trading day is -2.089%.
What is the most recent average sentiment score for NEUROCRINE BIOSCIENCES INC (NBIX:NASDAQ)?
The most recent average sentiment score for NEUROCRINE BIOSCIENCES INC (NBIX:NASDAQ) is 77 out of 100.
What is the most recent average sentiment for NEUROCRINE BIOSCIENCES INC (NBIX:NASDAQ)?
The most recent sentiment for NEUROCRINE BIOSCIENCES INC (NBIX:NASDAQ) is .
SEC-8K** Filing Available For NEUROCRINE BIOSCIENCES INC (NBIX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.